Pretreatment Features to Influence Effectiveness of Intravesical Hyaluronic Acid Instillation in Refractory Interstitial Cystitis/Painful Bladder Syndrome
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To determine the efficacy of intravesical hyaluronic acid (HA) instillation in treating patients with refractory interstitial cystitis/painful bladder syndrome (IC/PBS) and to identify any related factors that influence its therapeutic effect. Methods: Thirty-three female IC/PBS patients who demonstrated poor or unsatisfactory responses to previous treatments between December 2010 and October 2012 were enrolled. Despite previous treatments, the enrolled patients had visual analogue scale (VAS) pain scores ≥4 and total scores (symptom and bother scores) ≥13 on the pelvic pain and urgency/frequency (PUF) questionnaire and ≥12 on the O’Leary-Sant interstitial cystitis symptoms index (ICSI)/problems index (ICPI). All patients received once weekly intravesical instillations of 40-mg HA diluted in 50-mL saline for 4 weeks. The efficacy of the HA instillation was evaluated by comparing the mean changes in the scores of the VAS and questionnaires from baseline to 4 weeks after treatment. Improvement was defined as a ≥2 decrease in the VAS. Moreover, we investigated the effects of the presence of Hunner’s ulcer and previous treatment modalities on the therapeutic outcome of HA instillation. Results: The mean age was 57.0±1.8 years (range, 28–75 years). The VAS score significantly decreased from baseline to 4 weeks after treatment (–2.5, P<0.001). The mean changes in the PUF, ICSI, and ICPI from baseline to 4 weeks after the treatment were –3.8 (P<0.001), –2.3 (P<0.001), and –2.7 (P<0.001), respectively. Twenty patients (61%) showed improvements. Previous treatment modalities did not affect the efficacy of HA instillation and the presence of Hunner’s ulcer was unrelated to outcomes. No complications were observed. Conclusions: These results show that intravesical HA instillation is an effective and safe treatment for patients with refractory IC/PBS. Previous treatment modalities and presence of Hunner’s ulcer do not affect the efficacy of HA instillation.
Abstract
Purpose: To determine the efficacy of intravesical hyaluronic acid (HA) instillation in treating patients with refractory interstitial cystitis/painful bladder syndrome (IC/PBS) and to identify any related factors that influence its therapeutic effect. Methods: Thirty-three female IC/PBS patients who demonstrated poor or unsatisfactory responses to previous treatments between December 2010 and October 2012 were enrolled. Despite previous treatments, the enrolled patients had visual analogue scale (VAS) pain scores ≥4 and total scores (symptom and bother scores) ≥13 on the pelvic pain and urgency/frequency (PUF) questionnaire and ≥12 on the O’Leary-Sant interstitial cystitis symptoms index (ICSI)/problems index (ICPI). All patients received once weekly intravesical instillations of 40-mg HA diluted in 50-mL saline for 4 weeks. The efficacy of the HA instillation was evaluated by comparing the mean changes in the scores of the VAS and questionnaires from baseline to 4 weeks after treatment. Improvement was defined as a ≥2 decrease in the VAS. Moreover, we investigated the effects of the presence of Hunner’s ulcer and previous treatment modalities on the therapeutic outcome of HA instillation. Results: The mean age was 57.0±1.8 years (range, 28–75 years). The VAS score significantly decreased from baseline to 4 weeks after treatment (–2.5, P<0.001). The mean changes in the PUF, ICSI, and ICPI from baseline to 4 weeks after the treatment were –3.8 (P<0.001), –2.3 (P<0.001), and –2.7 (P<0.001), respectively. Twenty patients (61%) showed improvements. Previous treatment modalities did not affect the efficacy of HA instillation and the presence of Hunner’s ulcer was unrelated to outcomes. No complications were observed. Conclusions: These results show that intravesical HA instillation is an effective and safe treatment for patients with refractory IC/PBS. Previous treatment modalities and presence of Hunner’s ulcer do not affect the efficacy of HA instillation.
참고문헌 (27)
- Dell JR, "Interstitial cystitis", painful bladder syndrome: appropriate diagnosis and management, 2007, pp.16, 1181~1187
- Ömer Gülpınar, "Instillation of Hyaluronic Acid via Electromotive Drug Administration Can Improve the Efficacy of Treatment in Patients With Interstitial Cystitis", Painful Bladder Syndrome: A Randomized Prospective Study, 2014, pp.55(5), 354~359[DOI]
- Abrams P, "The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society", Urology, 61, pp.37~49 (2003)
- Leppilahti M, "Prevalence of symptoms related to interstitial cystitis in women: a population based study in Finland", J Urol, 168, pp.139~143 (2002)
- Kusek JW, "The epidemiology of interstitial cystitis: is it time to expand our definition?", Urology, 57(6 Suppl 1), pp.95~99 (2001)
- Choe JH, "Prevalence of painful bladder syndrome", interstitial cystitis-like symptoms in women: a population-based study in Korea, 2011, pp.29, 103~108
- Nickel JC, "Psychosocial phenotyping in women with interstitial cystitis", painful bladder syndrome: a case control study, 2010, pp.183, 167~172
- 함병국, "Effects of Combination Treatment of Intravesical Resiniferatoxin Instillation and Hydrodistention in Patients with Refractory Painful Bladder Syndrome", Interstitial Cystitis: A Pilot Study, 2012, pp.16(1), 41~46[DOI]
- Parsons CL, "Decreased urinary uronic acid levels in individuals with interstitial cystitis", J Urol, 143, pp.690~693 (1990)
- Lokeshwar VB, "Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity", J Urol, 176, pp.1001~1007 (2006)
- Porru D, "Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome", interstitial cystitis, 2012, pp.23, 1193~1199
- Morales A, "Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis", Urology, 49(5A Suppl), pp.111~113 (1997)
- Porru D, "Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid", Urol Int, 59, pp.26~29 (1997)
- Offiah I, "Interstitial cystitis", bladder pain syndrome: diagnosis and management, 2013, pp.24, 1243~1256
- Engelhardt PF, "Long-term results of intravesical hyaluronan therapy in bladder pain syndrome", interstitial cystitis, 2011, pp.22, 401~405
- Homma Y, "Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome", Int J Urol, 16, pp.597~615 (2009)
- Butrick CW, "Interstitial cystitis and chronic pelvic pain: new insights in neuropathology, diagnosis, and treatment", Clin Obstet Gynecol, 46, pp.811~823 (2003)
- 손환철, "Translation and Linguistic Validation of the Korean Version of the Pelvic Pain and Urgency", Frequency Patient Symptom Scale, 2010, pp.14(2), 112~121[DOI]
- Nickel JC, "Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis", Urology, 65, pp.654~658 (2005)
- Daha LK, "The effects of intravesical pentosanpolysulfate treatment on the symptoms of patients with bladder pain syndrome", interstitial cystitis: preliminary results, 2008, pp.19, 987~990
- Shao Y, "Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis", Urology, 75, pp.547~550 (2010)
- Hanno PM, "AUA guideline for the diagnosis and treatment of interstitial cystitis", bladder pain syndrome, 2011, pp.185, 2162~2170
- Hillelsohn JH, "Fulguration for Hunner ulcers: long-term clinical outcomes", J Urol, 188, pp.2238~2241 (2012)
- 류제만, "Elimination of Hunner’s Ulcers by Fulguration in Patients With Interstitial Cystitis: Is It Effective and Long Lasting?", Investigative and Clinical Urology, 54(11), pp.767~771 (2013), 대한비뇨기과학회
- Iavazzo C, "Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis?", Eur Urol, 51, pp.1534~1540 (2007)
- Morales A, "Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis", J Urol, 156, pp.45~48 (1996)
- Kallestrup EB, "Treatment of interstitial cystitis with cystistat: a hyaluronic acid product", Scand J Urol Nephrol, 39, pp.143~147 (2005)